Senior Director - Bioanalysis, ADME & Discovery Toxicology
Merck
Dr. Foti is a Senior Director at Merck where he leads drug disposition efforts for small molecules, peptides and protein therapeutics across multiple therapeutic areas. Prior to joining Merck, Rob held positions at Amgen, Inc., supporting multi-modality drug discovery and development efforts, and at Pfizer, contributing to high-throughput ADME assays. Collectively, Rob has over 20 years of driving innovative research in the pharmaceutical industry.
He received his undergraduate degree in chemical biology from Stevens Institute of Technology (Hoboken, NJ), his master’s in chemistry from Lehigh University (Bethlehem, PA) and his Ph.D. in molecular pharmacology from the University of Nice – Sophia Antipolis (Nice, France). Rob’s current research focuses on reverse translational pharmacology, cytochrome P450 and UGT enzymology, and biodistribution of drugs to the pharmacological site of action, resulting in over 50 peer-reviewed manuscripts, book chapters and invited reviews.
Externally, Rob is an Associate Editor for Drug Metabolism and Disposition, is on the Editorial Board for Xenobiotica and Drug Metabolism Letters and is a past Chair for the Drug Metabolism and Disposition Division of the American Society for Pharmacology and Experimental Therapeutics. Rob is a member of the ISSX and an ad hoc referee for multiple peer-reviewed journals.
Disclosure information not submitted.
Monday, October 17, 2022
8:30 AM – 9:00 AM ET